Ischemic Preconditioning to Prevent Acute Kidney Injury
Primary Purpose
Acute Kidney Injury
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ischemic preconditionin
Sponsored by
About this trial
This is an interventional prevention trial for Acute Kidney Injury
Eligibility Criteria
Inclusion Criteria:
- Stage III-IV chronic kidney disease (with serum creatinine at or above 1.4 mg/dl and eGFR 15-55 ml/min/1.73m2 calculated by the Modification of Diet in Renal Disease formula)
- Undergoing planned coronary angiography (including both cardiac and peripheral vascular) and/or intervention at KUMC
Exclusion Criteria:
- Patients with normal renal function (stage 0 to 2 chronic kidney disease and/or serum creatinine less than 1.4 mg/dl)
- Inability or unwillingness to provide consent
- Patients undergoing hemodialysis or peritoneal dialysis therapy
- Patients with renal artery stenting
- Hemodynamically unstable patients
- Patients with acute or acute on chronic heart failure
- Patients who are unable to undergo the study procedure due to any upper extremity problems such as prior amputation, prior radical mastectomy, etc
- Patients who have not been hydrated prior to procedure using the standard protocols
Sites / Locations
- University of Kansas Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Ischemic Preconditioning Group
Control Group
Arm Description
Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
Outcomes
Primary Outcome Measures
Acute Kidney Injury
Defined as an absolute increase in serum creatinine greater than or equal to 0.5 mg/dl or a relative increase of greater than or equal to 25% compared with pre-procedural baseline as compared to 48-72 hours post-angiography.
Secondary Outcome Measures
Progression of kidney disease
Defined as change in serum creatinine and epidermal growth factor receptor (eGFR)
Full Information
NCT ID
NCT02167152
First Posted
June 16, 2014
Last Updated
April 2, 2018
Sponsor
University of Kansas Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02167152
Brief Title
Ischemic Preconditioning to Prevent Acute Kidney Injury
Official Title
Ischemic Preconditioning to Prevent Acute Kidney Injury
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
February 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Kansas Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to learn about the impact of ischemic preconditioning in reducing contrast induced kidney damage in people with pre-existing kidney problems who are undergoing cardiac catheterization procedures.
Detailed Description
Ischemic preconditioning is thought to work by down-regulating pro-inflammatory gene expression and up-regulating anti-inflammatory gene expression in leukocytes. There is a local release of vasodilators, including adenosine and nitric oxide that are thought to have renal protective effects [16]. More is known regarding ischemic preconditioning in the heart, where it has been shown to decrease the adenine nucleotide pool, increase creatine phosphate and intracellular glucose, decrease ATP depletion, and lactate and H+ accumulation. This leads to sodium maintenance of the transmembrane sodium gradient that prevents intracellular edema. Ischemic preconditioning is thought to yield protection in the first minutes of reperfusion. Activation of the adenosine A1, bradykinin, and opioid receptors is thought to trigger protection. This is supported by the interference with protection if an adenosine receptor antagonist is administered. The role of reactive oxygen species as part of the protective mechanism has also been described via mitochondrial mKATP channels which lead to increased production of protective superoxide. Protein kinase C may also be involved in the protective mechanism of ischemic preconditioning, however the exact mechanism is unknown and controversial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
115 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ischemic Preconditioning Group
Arm Type
Experimental
Arm Description
Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
Intervention Type
Other
Intervention Name(s)
Ischemic preconditionin
Intervention Description
Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
Primary Outcome Measure Information:
Title
Acute Kidney Injury
Description
Defined as an absolute increase in serum creatinine greater than or equal to 0.5 mg/dl or a relative increase of greater than or equal to 25% compared with pre-procedural baseline as compared to 48-72 hours post-angiography.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Progression of kidney disease
Description
Defined as change in serum creatinine and epidermal growth factor receptor (eGFR)
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Stage III-IV chronic kidney disease (with serum creatinine at or above 1.4 mg/dl and eGFR 15-55 ml/min/1.73m2 calculated by the Modification of Diet in Renal Disease formula)
Undergoing planned coronary angiography (including both cardiac and peripheral vascular) and/or intervention at KUMC
Exclusion Criteria:
Patients with normal renal function (stage 0 to 2 chronic kidney disease and/or serum creatinine less than 1.4 mg/dl)
Inability or unwillingness to provide consent
Patients undergoing hemodialysis or peritoneal dialysis therapy
Patients with renal artery stenting
Hemodynamically unstable patients
Patients with acute or acute on chronic heart failure
Patients who are unable to undergo the study procedure due to any upper extremity problems such as prior amputation, prior radical mastectomy, etc
Patients who have not been hydrated prior to procedure using the standard protocols
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kamal Gupta, MD
Organizational Affiliation
University of Kansas Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Patrick Tobbia, MD
Organizational Affiliation
University of Kansas Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Ischemic Preconditioning to Prevent Acute Kidney Injury
We'll reach out to this number within 24 hrs